sparsentan
Marketedupdated 2mo agoby $TVTX Travere Therapeutics, Inc.
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for iga glomerulonephritis and 3 investigational indications.
all catalysts(5)
approval · 5
Feb 17, 2023
approval
FILSPARI (SPARSENTAN) — FDA approval
sparsentan
→
Oct 18, 2023
approval
FILSPARI (SPARSENTAN) — FDA approval
sparsentan
→
Sep 5, 2024
approval
FILSPARI (SPARSENTAN) — FDA approval
sparsentan
→
Aug 27, 2025
approval
FILSPARI (SPARSENTAN) — FDA approval
sparsentan
→
Apr 13, 2026
approval
FILSPARI (SPARSENTAN) — FDA approval
sparsentan
→
News(0)
no news has mentioned this drug yet
comments(0)
5-min edit window · permanent after that